Skip to main content

Anaptysbio, Inc (ANAB)

Sector
Biotechnology
Last price
$45.61
As of

Kresmion compiles this page from ANAB's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.

ANAPTYSBIO, INC (ANAB): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-11-12.

As of . Source: SEC EDGAR filings for ANAB. Method and limitations.

COMPANY DOSSIER

See the full ANAB dossier

Price with insider and filing markers, who is positioning, fundamentals and peers for ANAB on one page. Preview it with sample data, then open it live with a free account.

Preview the ANAB dossier

Active events for ANAB

FREE, NO ACCOUNT

Every event on ANAB, as it fires

You are seeing 5 of 9 events recorded on ANAB since 2026-06-18.

The five above landed across 2 days. The other 4 were recorded on 2 other days. 7 of the 9 are institutional flow rows, which arrive in batches on filing days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

No non-option holdings from tracked managers in this reporting quarter. Other reporting quarters are linked above.

Recent SEC filings, ANAB

More data on ANAB

ANAB against its peers

ANAB's operating margin of 20.4% ranks in the 88th percentile of 11 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.

MetricANABPeer medianPercentilen
Revenue FY235M USD16.1M USD7111
Gross marginn/a92.3%n/a5
Operating margin20.4%-651.7%8811
Net margin-5.6%-609.9%7911
Return on equity-35.6%-45.2%6816
1 year84.9%1.7%8117

Peers (19): KRSA, NVAX, NTLA, MLYS, LBRX, DMRA, URGN, IMCR, TSHA, TYRA, RAPP, GHRS, INBX, ABSI, SLS, QURE, PGEN, MNKD, FBRX.D. Left out: KALV.D (no annual filing), KARD (no annual filing), ADRX (no annual filing), AVLN (no annual filing), AAPG (period gap), LYCA (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (ANAB: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Cite this data

Kresmion counts the managers it follows that reported a non-option position in ANAB on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on ANAB in the last 180 days.

Upstream: SEC EDGAR filings for ANAB

Kresmion, "ANAPTYSBIO, INC (ANAB) institutional holdings and SEC filings", data as of 2026-11-12, https://kresmion.com/research/ANAB. Upstream data: SEC EDGAR filings for ANAB.

Link to this data (HTML):

<a href="https://kresmion.com/research/ANAB">ANAPTYSBIO, INC (ANAB) institutional holdings and SEC filings (Kresmion)</a>

Writing about this? Press contact and ready-to-quote figures

Follow ANAB on a live board

Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to ANAB for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.

Preview the ANAB dossier
Share

The ANAB intelligence card: the smart money composite, cross family confluence and the top current signal, with a link back to this page.